Preeclampsia: Short-term and Long-term Implications.

Preeclampsia is a hypertensive disorder that affects 4% of pregnancies and has a high risk of maternal, fetal, and neonatal morbidity and mortality, as well as long-term cardiovascular risk. Recent updates in the definition, diagnosis, and management guidelines for preeclampsia warrant review by general obstetrician-gynecologists. Screening and prevention algorithms for preeclampsia are available, but ultimately the cure remains delivery of the fetus and placenta. Close monitoring for the development and worsening of preeclampsia during pregnancy is essential to optimize both maternal and fetal/neonatal outcomes.

[1]  B. Sibai,et al.  Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. , 1998, The New England journal of medicine.

[2]  R. Mehran,et al.  Pre-eclampsia and future cardiovascular risk among women: a review. , 2014, Journal of the American College of Cardiology.

[3]  A. Odibo,et al.  Screening for abnormal placentation and adverse pregnancy outcomes with maternal serum biomarkers in the second trimester , 2014, Prenatal diagnosis.

[4]  D. Kallogjeri,et al.  Recurrence of Preeclampsia: Effects of Gestational Age at Delivery of the First Pregnancy, Body Mass Index, Paternity, and Interval Between Births , 2009 .

[5]  L. Poston,et al.  Adverse maternal and perinatal outcomes in women with previous preeclampsia: a prospective study , 2011, American journal of obstetrics and gynecology.

[6]  G. Macones,et al.  Magnesium for Seizure Prophylaxis in Patients With Mild Preeclampsia , 2007, Obstetrics and gynecology.

[7]  E. Ruppin,et al.  The use of aspirin to prevent pregnancy‐induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies , 1989, The New England journal of medicine.

[8]  M. Bots,et al.  Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. , 2006, American journal of obstetrics and gynecology.

[9]  Anne B Wallis,et al.  Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. , 2008, American journal of hypertension.

[10]  A. Caughey.  Creasy and Resnik’s Maternal-Fetal Medicine: Principles and Practice , 2009 .

[11]  T. O'brien,et al.  Maternal Body Mass Index and the Risk of Preeclampsia: A Systematic Overview , 2003, Epidemiology.

[12]  C. Ananth,et al.  Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis , 2013, BMJ.

[13]  B. Sibai,et al.  Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. , 1991, American journal of obstetrics and gynecology.

[14]  R. Pijnenborg,et al.  A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre‐eclamptic pregnancies , 1994, British journal of obstetrics and gynaecology.

[15]  Aeilko H. Zwinderman,et al.  Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis , 2008, Canadian Medical Association Journal.

[16]  B. Sibai.  Etiology and management of postpartum hypertension-preeclampsia. , 2012, American journal of obstetrics and gynecology.

[17]  C. Mulrow,et al.  MANAGEMENT OF MILD CHRONIC HYPERTENSION DURING PREGNANCY: A REVIEW , 2000, Obstetrics and gynecology.

[18]  F. Audibert,et al.  Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. , 2010, American journal of obstetrics and gynecology.

[19]  James M. Roberts,et al.  Hypertension in Pregnancy: Executive Summary , 2013 .

[20]  N. Trivedi.  A meta-analysis of low-dose aspirin for prevention of preeclampsia. , 2011, Journal of postgraduate medicine.

[21]  E. Gratacós,et al.  Predictive value of angiogenic factors and uterine artery Doppler for early‐ versus late‐onset pre‐eclampsia and intrauterine growth restriction , 2008, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[22]  B. Sibai.  Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. , 2004, American journal of obstetrics and gynecology.

[23]  G. Saade,et al.  First-Trimester Prediction of Preeclampsia in Nulliparous Women at Low Risk , 2012, Obstetrics and gynecology.

[24]  A. Benigni,et al.  Mapping the Theories of Preeclampsia and the Role of Angiogenic Factors: A Systematic Review , 2007, Obstetrics and gynecology.

[25]  François Audibert,et al.  Prevention of Preeclampsia and Intrauterine Growth Restriction With Aspirin Started in Early Pregnancy: A Meta-Analysis , 2010, Obstetrics and gynecology.

[26]  B. Sibai,et al.  Prediction and prevention of recurrent preeclampsia. , 2008, Obstetrics and gynecology.

[27]  K. Nicolaides,et al.  Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach , 2010, Journal of Human Hypertension.

[28]  M. Plana,et al.  First‐trimester uterine artery Doppler and adverse pregnancy outcome: a meta‐analysis involving 55 974 women , 2014, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[29]  Mandy J. Bell.  A historical overview of preeclampsia-eclampsia. , 2010, Journal of obstetric, gynecologic, and neonatal nursing : JOGNN.

[30]  Michael A Black,et al.  Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort , 2011, BMJ : British Medical Journal.

[31]  A. Hingorani,et al.  Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.

[32]  B. Sibai.  Evaluation and management of severe preeclampsia before 34 weeks' gestation. , 2011, American journal of obstetrics and gynecology.

[33]  J. Aarnoudse,et al.  Long‐term cerebral imaging after pre‐eclampsia , 2012, BJOG : an international journal of obstetrics and gynaecology.

[34]  L. Magee,et al.  Predicting adverse outcomes in women with severe pre-eclampsia. , 2009, Seminars in perinatology.

[35]  A. Hunter,et al.  Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. , 2004, American journal of obstetrics and gynecology.

[36]  Kirsten Duckitt,et al.  Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies , 2005, BMJ : British Medical Journal.

[37]  Risk Factors for Preeclampsia, Abruptio Placentae, and Adverse Neonatal Outcomes among Women with Chronic Hypertension , 1998 .

[38]  H. Wallenburg,et al.  LOW-DOSE ASPIRIN PREVENTS PREGNANCY-INDUCED HYPERTENSION AND PRE-ECLAMPSIA IN ANGIOTENSIN-SENSITIVE PRIMIGRAVIDAE , 1986, The Lancet.

[39]  Amber Samuel,et al.  Can the quantity of cell‐free fetal DNA predict preeclampsia: a systematic review , 2014, Prenatal diagnosis.

[40]  H. Honest,et al.  Aspirin for Prevention of Preeclampsia in Women With Historical Risk Factors: A Systematic Review , 2003, Obstetrics and gynecology.